Evrópusambandið - íslenska - EMA (European Medicines Agency)

eisai gmbh - perampanel - flogaveiki, partial - antiepileptics, , Önnur antiepileptics - fycompa er ætlað til viðbótarmeðferðar við flogaveiki með eða án sekúndu með almennum flogum hjá fullorðnum og unglingum frá 12 ára aldri með flogaveiki. mælt er ætlað fyrir venjulega meðferð aðal almenn tonic-m krampa í fullorðinn og unglingur sjúklingar frá 12 ára aldri með sjálfvakin almenn flogaveiki.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepín asetat - flogaveiki - antiepileptics, - zebinix er ætlað sem viðbótarmeðferð hjá fullorðnum, unglingum og börnum eldri en 6 ára, með flogaveiki með eða án aukakvilla.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - eslicarbazepinum acetat - tafla - 800 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - eslicarbazepinum acetat - tafla - 200 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Æxlishemjandi lyf - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Æxlishemjandi lyf - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - methotrexatum inn - tafla - 2,5 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mitsubishi pharma europe ltd - colestilan - hyperphosphatemia - lyf til að meðhöndla blóðkalíumhækkun og blóðfosfatíumlækkun - meðferð við blóðfosfatskorti hjá fullorðnum sjúklingum með stigs nýrnasjúkdóms stig 5 sem fá blóðskilun eða kviðskilun.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mergæxli - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 150 mg